Trial Outcomes & Findings for Study to Evaluate Menses Induction in Women Administered Proellex (NCT NCT00881608)

NCT ID: NCT00881608

Last Updated: 2014-08-25

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE1

Target enrollment

11 participants

Primary outcome timeframe

An early vaginal bleeding event lasting at least two days and occurring on or before day 24 will be deemed to have achieved an induced menses

Results posted on

2014-08-25

Participant Flow

Participant milestones

Participant milestones
Measure
All Subjects Enrolled
All subjects initiated treatment with placebo. Further information is not availasble due to premature termination of the study.
Overall Study
STARTED
11
Overall Study
COMPLETED
0
Overall Study
NOT COMPLETED
11

Reasons for withdrawal

Reasons for withdrawal
Measure
All Subjects Enrolled
All subjects initiated treatment with placebo. Further information is not availasble due to premature termination of the study.
Overall Study
Study prematurely terminated
11

Baseline Characteristics

Study to Evaluate Menses Induction in Women Administered Proellex

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: An early vaginal bleeding event lasting at least two days and occurring on or before day 24 will be deemed to have achieved an induced menses

Population: Study prematurely terminated

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At least 2 days

Population: Study prematurely terminated

Outcome measures

Outcome data not reported

Adverse Events

Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

3 mg Proellex

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

6 mg Proellex

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

12 mg Proellex

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

25 mg Proellex

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jennifer Wike

Repros Therapeutics

Phone: 2817193402

Results disclosure agreements

  • Principal investigator is a sponsor employee Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights
  • Publication restrictions are in place

Restriction type: OTHER